Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) have earned a consensus rating of “Moderate Buy” from the seven research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $6.40.

A number of equities analysts have weighed in on MIST shares. Zacks Research raised Milestone Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th. Wells Fargo & Company cut their target price on Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating for the company in a research note on Thursday, May 14th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a report on Tuesday, July 14th. Cantor Fitzgerald started coverage on shares of Milestone Pharmaceuticals in a research report on Thursday, August 20th. They set an “overweight” rating and a $3.00 price target on the stock. Finally, Wall Street Zen lowered shares of Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Sunday, May 17th.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. HighTower Advisors LLC increased its stake in Milestone Pharmaceuticals by 100.0% during the second quarter. HighTower Advisors LLC now owns 20,000 shares of the company’s stock worth $27,000 after acquiring an additional 10,000 shares during the last quarter. Guardian Wealth Advisors LLC NC grew its holdings in shares of Milestone Pharmaceuticals by 21.1% during the 2nd quarter. Guardian Wealth Advisors LLC NC now owns 339,450 shares of the company’s stock worth $455,000 after purchasing an additional 59,200 shares during the period. ADAR1 Capital Management LLC purchased a new position in shares of Milestone Pharmaceuticals during the 2nd quarter worth $134,000. TRU Independence Asset Management 2 LLC purchased a new stake in Milestone Pharmaceuticals in the 2nd quarter valued at about $201,000. Finally, Bay Rivers Group lifted its position in Milestone Pharmaceuticals by 55.9% in the second quarter. Bay Rivers Group now owns 46,633 shares of the company’s stock valued at $62,000 after buying an additional 16,722 shares during the last quarter. 86.18% of the stock is currently owned by hedge funds and other institutional investors.

Milestone Pharmaceuticals Stock Up 3.5%

MIST stock opened at $1.18 on Thursday. The company has a current ratio of 8.13, a quick ratio of 7.92 and a debt-to-equity ratio of 3.25. The firm has a 50-day moving average of $1.19 and a two-hundred day moving average of $1.45. Milestone Pharmaceuticals has a 12 month low of $1.00 and a 12 month high of $3.06. The company has a market cap of $146.91 million, a price-to-earnings ratio of -1.71 and a beta of 0.98.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its earnings results on Wednesday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The firm had revenue of $0.56 million during the quarter, compared to analyst estimates of $0.82 million. As a group, analysts forecast that Milestone Pharmaceuticals will post -0.84 earnings per share for the current fiscal year.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.